Literature DB >> 17484755

Epilepsy in phenylketonuria: a complex dependence on serum phenylalanine levels.

Anatoly E Martynyuk1, Deniz A Ucar, Dawn D Yang, Wendy M Norman, Paul R Carney, Donn M Dennis, Philip J Laipis.   

Abstract

PURPOSE: Phenylketonuria (PKU) is a disorder of phenylalanine (Phe) metabolism that frequently results in epilepsy if a low Phe diet was not implemented at birth. The mechanisms by which Phe affects the brain are poorly understood.
METHODS: Audiogenic seizures (AGS) were studied in female homozygous Pah(enu2) BTBR (PKU) mice.
RESULTS: Adult PKU mice, 18-20 weeks of age, in contrast to wild-type and heterozygous counterparts, exhibited a full range of AGS. Younger PKU mice, 5-7 weeks of age, had higher serum Phe levels (2.22 +/- 0.20 mM) in comparison with the adult animals (1.72 +/- 0.05 mM) and were not susceptible to AGS. Among adult mice, animals susceptible to AGS had significantly lower serum Phe levels (1.62 +/- 0.06 mM) in comparison with those resistant to AGS (1.86 +/- 0.07 mM). Susceptibility to AGS tended to increase in the afternoon when serum Phe concentration decreased in comparison to evening and morning. Normalization of serum Phe level by instituting a low Phe diet generally prevented susceptibility to AGS within 12 h. Although return to a standard diet raised Phe levels to hyperphenylalaninemic within 12 h in animals treated with a low Phe diet for 2 weeks, more than 7 weeks were needed for a complete resumption of AGS.
CONCLUSIONS: Transient decrease in Phe levels within hyperphenylalaninemic range may be a necessary condition for PKU-related seizures to occur. A low Phe diet prevents susceptibility to seizures, which can resume with the significant delay after termination of dietary treatment.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17484755     DOI: 10.1111/j.1528-1167.2007.01115.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  9 in total

1.  Generalized seizures aggravated by levetiracetam in an adult patient with phenylketonuria.

Authors:  Nese Dericioglu; Serap Saygi
Journal:  Metab Brain Dis       Date:  2010-04-28       Impact factor: 3.584

2.  A retrospective analysis of metabolic control in children with PKU in the COVID-19 era.

Authors:  Dóra Becsei; Erika Kiss; Ildikó Szatmári; András Arató; György Reusz; Attila J Szabó; János Bókay; Petra Zsidegh
Journal:  Mol Genet Metab Rep       Date:  2022-07-08

3.  Biochemical, Metabolic, and Behavioral Characteristics of Immature Chronic Hyperphenylalanemic Rats.

Authors:  Gerald A Dienel; Nancy F Cruz
Journal:  Neurochem Res       Date:  2015-07-30       Impact factor: 3.996

4.  Epilepsy and phenylketonuria: a case description and EEG-fMRI findings.

Authors:  Melania Guida; Ilaria Pesaresi; Serena Fabbri; Ferdinando Sartucci; Mirco Cosottini; Filippo Sean Giorgi
Journal:  Funct Neurol       Date:  2014 Jan-Mar

Review 5.  Metabolic etiologies in West syndrome.

Authors:  Seda Salar; Solomon L Moshé; Aristea S Galanopoulou
Journal:  Epilepsia Open       Date:  2018-03-14

6.  Maternal phenylketonuria syndrome: studies in mice suggest a potential approach to a continuing problem.

Authors:  William L Zeile; Helen C McCune; Donald G Musson; Brian O'Donnell; Charles A O'Neill; Laurie S Tsuruda; Roberto T Zori; Philip J Laipis
Journal:  Pediatr Res       Date:  2018-01-31       Impact factor: 3.756

7.  Lifetime Cost Effectiveness of Phenylketonuria Screening National Program in Iran.

Authors:  Alireza Heidari; Mohammad Arab; Behzad Damari
Journal:  Iran J Public Health       Date:  2021-10       Impact factor: 1.429

8.  Quality of life in children living with PKU - a single-center, cross-sectional, observational study from Hungary.

Authors:  Dóra Becsei; Réka Hiripi; Erika Kiss; Ildiko Szatmári; András Arató; György Reusz; Attila J Szabó; János Bókay; Petra Zsidegh
Journal:  Mol Genet Metab Rep       Date:  2021-11-16

9.  Formulation and PEGylation optimization of the therapeutic PEGylated phenylalanine ammonia lyase for the treatment of phenylketonuria.

Authors:  Sean M Bell; Dan J Wendt; Yanhong Zhang; Timothy W Taylor; Shinong Long; Laurie Tsuruda; Bin Zhao; Phillip Laipis; Paul A Fitzpatrick
Journal:  PLoS One       Date:  2017-03-10       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.